PGEN Precigen Inc

Price (delayed)

$1.365

Market cap

$283.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.48

Enterprise value

$455.75M

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases ...

Highlights
PGEN's quick ratio is up by 36% from the previous quarter and by 6% YoY
PGEN's gross profit is up by 14% year-on-year and by 7% since the previous quarter
Precigen's EPS has increased by 37% YoY but it has decreased by 2.1% QoQ
PGEN's net income is up by 29% year-on-year but it is down by 2.1% since the previous quarter
PGEN's equity has dropped by 58% year-on-year and by 31% since the previous quarter
Precigen's debt has increased by 15% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of PGEN
Market
Shares outstanding
207.69M
Market cap
$283.5M
Enterprise value
$455.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.83
Price to sales (P/S)
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.09
Earnings
Revenue
$111.38M
EBIT
-$77.84M
EBITDA
-$64.31M
Free cash flow
-$64.77M
Per share
EPS
-$0.48
Free cash flow per share
-$0.32
Book value per share
$0.36
Revenue per share
$0.56
TBVPS
$1.15
Balance sheet
Total assets
$335.57M
Total liabilities
$261.73M
Debt
$212.57M
Equity
$73.84M
Working capital
$129.34M
Liquidity
Debt to equity
2.88
Current ratio
6.05
Quick ratio
5.35
Net debt/EBITDA
-2.68
Margins
EBITDA margin
-57.7%
Gross margin
43.9%
Net margin
-84.5%
Operating margin
-71.4%
Efficiency
Return on assets
-25.5%
Return on equity
-79.8%
Return on invested capital
-20.1%
Return on capital employed
-25.1%
Return on sales
-69.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PGEN stock price

How has the Precigen stock price performed over time
Intraday
-5.21%
1 week
5.81%
1 month
-1.09%
1 year
-78.9%
YTD
-63.21%
QTD
-35.31%

Financial performance

How have Precigen's revenue and profit performed over time
Revenue
$111.38M
Gross profit
$48.88M
Operating income
-$79.58M
Net income
-$94.1M
Gross margin
43.9%
Net margin
-84.5%
Precigen's net margin has increased by 37% YoY and by 4.7% from the previous quarter
PGEN's net income is up by 29% year-on-year but it is down by 2.1% since the previous quarter
PGEN's operating margin is up by 21% YoY and by 7% from the previous quarter
PGEN's gross profit is up by 14% year-on-year and by 7% since the previous quarter

Growth

What is Precigen's growth rate over time

Valuation

What is Precigen stock price valuation
P/E
N/A
P/B
3.83
P/S
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.09
Precigen's EPS has increased by 37% YoY but it has decreased by 2.1% QoQ
PGEN's equity has dropped by 58% year-on-year and by 31% since the previous quarter
PGEN's P/B is 45% below its 5-year quarterly average of 7.4 and 45% below its last 4 quarters average of 7.3
PGEN's P/S is 72% below its 5-year quarterly average of 9.3 and 69% below its last 4 quarters average of 8.4
Precigen's revenue has increased by 14% YoY and by 7% from the previous quarter

Efficiency

How efficient is Precigen business performance
PGEN's return on equity is up by 47% year-on-year but it is down by 24% since the previous quarter
Precigen's return on sales has increased by 40% YoY
The ROIC has grown by 35% YoY but it has contracted by 9% from the previous quarter
The ROA has grown by 31% YoY but it has contracted by 7% from the previous quarter

Dividends

What is PGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PGEN.

Financial health

How did Precigen financials performed over time
The company's total assets is 28% higher than its total liabilities
PGEN's quick ratio is up by 36% from the previous quarter and by 6% YoY
PGEN's current ratio is up by 34% since the previous quarter and by 6% year-on-year
Precigen's debt is 188% more than its equity
PGEN's debt to equity has soared by 174% YoY and by 59% from the previous quarter
PGEN's equity has dropped by 58% year-on-year and by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.